Mefloquine, artesunate, mefloquine-artesunate and tribendimidine in the treatment of Opisthorchis viverrini infection in Laos

Swiss Tropical and Public Health Insitute (Switzerland)0 个研究点目标入组 100 人开始时间: 2010年3月16日最近更新: 2015年1月13日

试验速览

暂无简介。

•1. Patients (male and female schoolchildren older than 8 years) infected with O. viverrini, as assessed by the presence of eggs in the stool
•2. Weight of patient greater than 25 kg
•3. Able and willing to be examined by a study physician at the beginning of the study and at the end-of study (3 weeks post-treatment)
•4. Able and willing to provide multiple stool samples at the beginning and end of study
•5. Absence of major systemic illnesses, as assessed by the medical doctor, upon initial clinical assessment
•6. Absence of psychiatric and neurological disorders
•7. No known or reported hypersensitivity to mefloquine, tribendimidine and/or artesunate
•8. No known or reported history of chronic illness as cancer, diabetes, chronic heart, liver or renal disease
•9. Signed written informed consent sheet
•10. For females aged 12 years and above, not pregnant in the first trimester, as assessed by a pregnancy test, upon initial clinical assessment

•1. Pregnancy first trimester
•2. Presence of any abnormal medical condition, judged by the study physician
•3. History of acute or severe chronic disease
•4. Known or reported psychiatric or neurological disorders
•5. Use of artesunate, artemether, any ACT, mefloquine or praziquantel within the past month
•6. Attending other clinical trials during the study

发起方

Swiss Tropical and Public Health Insitute (Switzerland)